ATE518854T1 - Arylcarbonsäurecyclohexylamidderivate - Google Patents

Arylcarbonsäurecyclohexylamidderivate

Info

Publication number
ATE518854T1
ATE518854T1 AT08709083T AT08709083T ATE518854T1 AT E518854 T1 ATE518854 T1 AT E518854T1 AT 08709083 T AT08709083 T AT 08709083T AT 08709083 T AT08709083 T AT 08709083T AT E518854 T1 ATE518854 T1 AT E518854T1
Authority
AT
Austria
Prior art keywords
arylcarboxic
acidcyclohexylamide
derivatives
arylcarboxic acidcyclohexylamide
acidcyclohexylamide derivatives
Prior art date
Application number
AT08709083T
Other languages
English (en)
Inventor
Rene Hersperger
Philipp Janser
Wolfgang Miltz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE518854T1 publication Critical patent/ATE518854T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
AT08709083T 2007-02-19 2008-02-18 Arylcarbonsäurecyclohexylamidderivate ATE518854T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19
PCT/EP2008/051951 WO2008101905A1 (en) 2007-02-19 2008-02-18 Aryl carboxylic acid cyclohexyl amide derivatives

Publications (1)

Publication Number Publication Date
ATE518854T1 true ATE518854T1 (de) 2011-08-15

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08709083T ATE518854T1 (de) 2007-02-19 2008-02-18 Arylcarbonsäurecyclohexylamidderivate

Country Status (36)

Country Link
US (1) US8354431B2 (de)
EP (1) EP2125782B1 (de)
JP (1) JP5180234B2 (de)
KR (1) KR101070984B1 (de)
CN (1) CN101605781B (de)
AR (1) AR065369A1 (de)
AT (1) ATE518854T1 (de)
AU (1) AU2008219317B2 (de)
BR (1) BRPI0807625A2 (de)
CA (1) CA2677565C (de)
CL (1) CL2008000497A1 (de)
CR (1) CR10957A (de)
CY (1) CY1111984T1 (de)
DK (1) DK2125782T3 (de)
EA (1) EA017000B1 (de)
EC (1) ECSP099584A (de)
ES (1) ES2371126T3 (de)
GT (1) GT200900226A (de)
HK (1) HK1138836A1 (de)
HN (1) HN2009001607A (de)
HR (1) HRP20110793T1 (de)
IL (1) IL200191A (de)
MA (1) MA31206B1 (de)
MX (1) MX2009008145A (de)
MY (1) MY147487A (de)
NZ (1) NZ578663A (de)
PE (1) PE20081785A1 (de)
PL (1) PL2125782T3 (de)
PT (1) PT2125782E (de)
RS (1) RS51986B (de)
SI (1) SI2125782T1 (de)
TN (1) TN2009000345A1 (de)
TW (1) TW200848038A (de)
UA (1) UA97389C2 (de)
WO (1) WO2008101905A1 (de)
ZA (1) ZA200905160B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532570B2 (ja) 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
EP2034023A1 (de) 1996-03-01 2009-03-11 Euroscreen S.A. CC-Chemokinzeptor C-C CKR-5, dessen Derivate und Verwendungen
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
BR9813691A (pt) * 1997-12-19 2000-10-10 Takeda Chemical Industries Ltd Composição farmacêutica para antagonizar o ccr5, uso do composto ou um sal deste em combinação com um inibidor de protease e/ou um inibidor da transcriptase reversa, e, processo para antagonizar o ccr5.
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
CA2353635A1 (en) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
WO2001051077A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
CA2421842A1 (en) 2000-09-08 2002-03-14 Micromet Ag Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
CZ2004442A3 (cs) 2001-10-03 2005-03-16 Ucb, S.A. Pyrrolidinonové deriváty
US20060251651A1 (en) * 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
WO2004098638A1 (ja) * 2003-05-06 2004-11-18 Ono Pharmaceutical Co., Ltd. エフェクター細胞機能阻害剤
GB2423472A (en) * 2003-12-11 2006-08-30 Univ Yale Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
US7576089B2 (en) * 2003-12-18 2009-08-18 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005247361B2 (en) * 2004-05-11 2011-03-17 Incyte Corporation 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2007062175A2 (en) 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
EP2043640A2 (de) 2006-06-12 2009-04-08 Pfizer Products Inc. Ccr5-antagonist zur verbesserung der immunrekonstitution und behandlung von opportunistischen infektionen bei hiv-patienten
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
MX2009003762A (es) 2006-10-05 2009-07-10 Centocor Ortho Biotech Inc Antagonistas del receptor cc-quimiocina 2 para el tratamiento de fibrosis.
AR063275A1 (es) 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
WO2008060621A2 (en) 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
US20100267765A1 (en) 2007-02-15 2010-10-21 Stephen John Felstead Pharmaceutical Compositions and Methods for CCR5 Antagonists
EP2150817A4 (de) 2007-04-30 2011-09-07 Progenics Pharm Inc Verfahren zur reduktion der viruslast bei hiv-1-infizierten patienten

Also Published As

Publication number Publication date
ES2371126T3 (es) 2011-12-27
TN2009000345A1 (en) 2010-12-31
US8354431B2 (en) 2013-01-15
DK2125782T3 (da) 2011-11-21
HK1138836A1 (en) 2010-09-03
IL200191A (en) 2013-12-31
JP5180234B2 (ja) 2013-04-10
PL2125782T3 (pl) 2011-12-30
HRP20110793T1 (hr) 2011-11-30
RS51986B (en) 2012-02-29
EA200901085A1 (ru) 2010-02-26
CN101605781B (zh) 2014-08-13
CY1111984T1 (el) 2015-11-04
UA97389C2 (en) 2012-02-10
CR10957A (es) 2009-09-01
ZA200905160B (en) 2010-05-26
GT200900226A (es) 2010-07-02
WO2008101905A1 (en) 2008-08-28
AU2008219317B2 (en) 2011-09-08
HN2009001607A (es) 2011-11-23
EA017000B1 (ru) 2012-09-28
ECSP099584A (es) 2009-09-29
EP2125782B1 (de) 2011-08-03
TW200848038A (en) 2008-12-16
IL200191A0 (en) 2010-04-15
MY147487A (en) 2012-12-14
PT2125782E (pt) 2011-11-17
PE20081785A1 (es) 2009-01-12
SI2125782T1 (sl) 2011-12-30
CL2008000497A1 (es) 2008-08-29
NZ578663A (en) 2011-01-28
CN101605781A (zh) 2009-12-16
MX2009008145A (es) 2009-08-12
US20100016361A1 (en) 2010-01-21
CA2677565A1 (en) 2008-08-28
BRPI0807625A2 (pt) 2014-05-27
KR101070984B1 (ko) 2011-10-06
KR20090103943A (ko) 2009-10-01
JP2010519187A (ja) 2010-06-03
EP2125782A1 (de) 2009-12-02
AU2008219317A1 (en) 2008-08-28
MA31206B1 (fr) 2010-02-01
CA2677565C (en) 2014-11-18
AR065369A1 (es) 2009-06-03

Similar Documents

Publication Publication Date Title
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
ATE518837T1 (de) Indazolamidderivate
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
DK2308877T3 (da) Imidazopyridin-2-on-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
DK2152370T3 (da) Aryletherpyridazinonderivater
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2190837T3 (da) 4-pyrimidinsulfamid-derivat
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
ATE519760T1 (de) Isoxazolimidazolderivate
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
ATE546446T1 (de) 5-aminocyclylmethyl-oxazolidin-2-eins-derivativ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2125782

Country of ref document: EP